Psagot Value Holdings’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Psagot Value Holdings’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,683	Closed	-$240K	–	408
2019 Q1	$240K	Hold	3,683	–	–	0.01%	249
2018 Q4	$196K	Hold	3,683	–	–	0.01%	256
2018 Q3	$211K	Hold	3,683	–	–	0.01%	208
2018 Q2	$215K	Buy	3,683 +1,075	+41%	+$63.2K	0.01%	211
2018 Q1	$123K	Hold	2,608	–	–	0.01%	251
2017 Q4	$153K	Hold	2,608	–	–	0.01%	216
2017 Q3	$161K	Hold	2,608	–	–	0.01%	231
2017 Q2	$162K	Hold	2,608	–	–	0.01%	216
2017 Q1	$166K	Sell	2,608 -6	-0.2%	-$312	0.01%	220
2016 Q4	$100K	Hold	2,614	–	–	﹤0.01%	227
2016 Q3	$94K	Buy	2,614 +1,100	+73%	+$41.2K	﹤0.01%	248
2016 Q2	$55K	Hold	1,514	–	–	﹤0.01%	252
2016 Q1	$61K	Buy	1,514 +800	+112%	+$29.4K	﹤0.01%	292
2015 Q4	$31K	Hold	714	–	–	﹤0.01%	318
2015 Q3	$25K	Hold	714	–	–	﹤0.01%	317
2015 Q2	$39K	Hold	714	–	–	﹤0.01%	322
2015 Q1	$48K	Buy	+714	New	+$45.2K	﹤0.01%	300

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Psagot Value Holdings's BCLI Position: Q2 2019 in Review

Psagot Value Holdings sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2019, closing a stake of 3,683 shares — an estimated $240K sold.

Psagot Value Holdings first reported a position in BCLI in Q1 2015 and held it in 17 quarters. The position peaked at $240K in Q1 2019. 37 funds tracked by Wall St. Rank hold BCLI as of Q2 2019.

Psagot Value Holdings reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2019 after selling out during the quarter.
Psagot Value Holdings sold 3,683 BRAINSTORM CELL THERAPUTC shares in Q2 2019, an estimated $240K.
Psagot Value Holdings first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 17 quarters.
Psagot Value Holdings's BRAINSTORM CELL THERAPUTC position peaked at $240K in Q1 2019.
37 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2019.

Based on Psagot Value Holdings's 13F filing for Q2 2019, filed 29 Jul 2019.